Citations

Clear

3942 citation(s) found for "To, Van".

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas
Carlson, Matthew L. , Adewumi, Dare A, Hadjipanayis, Constantinos G., Uhm, Joon H. , Gompel, Jamie J. Van , Agazzi, Siviero , Adewumi, Dare A., Olson, Jeffrey J.

Mayo Clinic

Neurosurgery | October 27, 2017 | Volume: 82 | Issue: 2 | Pages: E52-E54

10.1093/neuros/nyx516 | PMID 29309638 Get It

Abstract MEDICAL THERAPY Target Population Adults with histologically proven or suspected vestibular schwannomas with neurofibromatosis type 2 (NF2). Question What is the role of bevacizumab in the treatment of patients with vestibular schwannomas? Recommendations Level 3: It is recommended that bevacizumab be administered in order to radiographically reduce the size or prolong tumor stability in patients with NF2 without surgical options. Level 3: It is recommended that bevacizumab be administered to improve hearing or prolong time to hearing loss in patients with NF2 without surgical options. Question Is there a role for lapatinib, erlotinib, or everolimus in the treatment of patients with vestibular schwannomas? Recommendations Level 3: Lapatinib may be considered for use in reducing vestibular schwannoma size and improvement in hearing in NF2. Level 3: Erlotinib is not recommended for use in reducing vestibular schwannoma size or improvement in hearing in patients with NF2. Level 3: Everolimus is not recommended for use in reducing vestibular schwannoma size or improvement in hearing in NF2. Question What is the role of aspirin, to augment inflammatory response, in the treatment of patients with vestibular schwannomas? Target Population Any patient with a vestibular schwannoma undergoing observation. Recommendation Level 3: It is recommended that aspirin administration may be considered for use in patients undergoing observation of their vestibular schwannomas. Question Is there a role for treatment of vasospasm, ie, nimodipine or hydroxyethyl starch, perioperatively to improve facial nerve outcomes in patients with vestibular schwannomas? Target Population Adults with histologically proven or suspected vestibular schwannomas. Recommendation Level 3: Perioperative treatment with nimodipine (or with the addition of hydroxyethyl starch) should be considered to improve postoperative facial nerve outcomes and may improve hearing outcomes. PREHABILITATION Question Is there a role for preoperative vestibular rehab or vestibular ablation with gentamicin for patients surgically treated for vestibular schwannomas? Target Population Adults with histologically proven or suspected vestibular schwannomas. Recommendations Level 3: Preoperative vestibular rehabilitation is recommended to aid in postoperative mobility after vestibular schwannoma surgery. Level 3: Preoperative gentamicin ablation of the vestibular apparatus should be considered to improve postoperative mobility after vestibular schwannoma surgery. SURGICAL THERAPY Question Does endoscopic assistance make a difference in resection or outcomes in patients with vestibular schwannomas? Target Population Vestibular schwannoma patients, who are surgical candidates. Inclusion in this analysis required resection utilizing the endoscope, either as the primary operative visualization or microscopic assistance with more than 20 patients treated. Recommendation Level 3: Endoscopic assistance is a surgical technique that the surgeon may choose to use in order to aid in visualization. The full guideline can be found at: https://www.cns.org/guidelines/guidelines-management-patients-vestibular-schwannoma/chapter_9.
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Pathological Methods and Prognostic Factors in Vestibular Schwannomas
Sughrue, Michael E. , Fung, Kar‐Ming , Peterson, Jo Elle G., Gompel, Jamie J. Van , Olson, Jeffrey J.

Mayo Clinic

Neurosurgery | October 27, 2017 | Volume: 82 | Issue: 2 | Pages: E47-E48

10.1093/neuros/nyx514 | PMID 29309662 Get It

Abstract TARGET POPULATION Adults diagnosed with vestibular schwannomas. QUESTION 1 What is the prognostic significance of Antoni A vs B histologic patterns in vestibular schwannomas? RECOMMENDATION No recommendations can be made due to a lack of adequate data. QUESTION 2 What is the prognostic significance of mitotic figures seen in vestibular schwannoma specimens? RECOMMENDATION No recommendations can be made due to a lack of adequate data. QUESTION 3 Are there other light microscopic features that predict clinical behavior of vestibular schwannomas? RECOMMENDATION No recommendations can be made due to a lack of adequate data. QUESTION 4 Does the KI-67 labeling index predict clinical behavior of vestibular schwannomas? RECOMMENDATION No recommendations can be made due to a lack of adequate data. QUESTION 5 Does the proliferating cell nuclear antigen labeling index predict clinical behavior of vestibular schwannomas? RECOMMENDATION No recommendations can be made due to a lack of adequate data. QUESTION 6 Does degree of vascular endothelial growth factor expression predict clinical behavior of vestibular schwannomas? RECOMMENDATION No recommendations can be made due to a lack of adequate data. The full guideline can be found at: https://www.cns.org/guidelines/guidelines-management-patients-vestibular-schwannoma/chapter_6.
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Surgical Resection for the Treatment of Patients With Vestibular Schwannomas
Hadjipanayis, Constantinos G., Carlson, Matthew L. , Link, Michael J. , Rayan, Tarek, Parish, John, Atkins, Tyler , Asher, Anthony L. , Dunn, Ian F. , Corrales, C. Eduardo , Sughrue, Michael E. , Rayan, Tarek A, Parish, John, Gompel, Jamie J. Van , Olson, Jeffrey J.

Mayo Clinic

Neurosurgery | October 27, 2017 | Volume: 82 | Issue: 2 | Pages: E40-E43

10.1093/neuros/nyx512 | PMID 29309632 Get It

Abstract Please see the full-text version of this guideline (https://www.cns.org/guidelines/guidelines-management-patients-vestibular-schwannoma/chapter_8) for the target population of each recommendation listed below. QUESTION 1 What surgical approaches for vestibular schwannomas (VS) are best for complete resection and facial nerve (FN) preservation when serviceable hearing is present? RECOMMENDATION There is insufficient evidence to support the superiority of either the middle fossa (MF) or the retrosigmoid (RS) approach for complete VS resection and FN preservation when serviceable hearing is present. QUESTION 2 Which surgical approach (RS or translabyrinthine [TL]) for VS is best for complete resection and FN preservation when serviceable hearing is not present? RECOMMENDATION There is insufficient evidence to support the superiority of either the RS or the TL approach for complete VS resection and FN preservation when serviceable hearing is not present. QUESTION 3 Does VS size matter for facial and vestibulocochlear nerve preservation with surgical resection? RECOMMENDATION Level 3: Patients with larger VS tumor size should be counseled about the greater than average risk of loss of serviceable hearing. QUESTION 4 Should small intracanalicular tumors (<1.5 cm) be surgically resected? RECOMMENDATION There are insufficient data to support a firm recommendation that surgery be the primary treatment for this subclass of VSs. QUESTION 5 Is hearing preservation routinely possible with VS surgical resection when serviceable hearing is present? RECOMMENDATION Level 3: Hearing preservation surgery via the MF or the RS approach may be attempted in patients with small tumor size (<1.5 cm) and good preoperative hearing. QUESTION 6 When should surgical resection be the initial treatment in patients with neurofibromatosis type 2 (NF2)? RECOMMENDATION There is insufficient evidence that surgical resection should be the initial treatment in patients with NF2. QUESTION 7 Does a multidisciplinary team, consisting of neurosurgery and neurotology, provides the best outcomes of complete resection and facial/vestibulocochlear nerve preservation for patients undergoing resection of VSs? RECOMMENDATION There is insufficient evidence to support stating that a multidisciplinary team, usually consisting of a neurosurgeon and a neurotologist, provides superior outcomes compared to either subspecialist working alone. QUESTION 8 Does a subtotal surgical resection of a VS followed by stereotactic radiosurgery (SRS) to the residual tumor provide comparable hearing and FN preservation to patients who undergo a complete surgical resection? RECOMMENDATION There is insufficient evidence to support subtotal resection (STR) followed by SRS provides comparable hearing and FN preservation to patients who undergo a complete surgical resection. QUESTION 9 Does surgical resection of VS treat preoperative balance problems more effectively than SRS? RECOMMENDATION There is insufficient evidence to support either surgical resection or SRS for treatment of preoperative balance problems. QUESTION 10 Does surgical resection of VS treat preoperative trigeminal neuralgia more effectively than SRS? RECOMMENDATION Level 3: Surgical resection of VSs may be used to better relieve symptoms of trigeminal neuralgia than SRS. QUESTION 11 Is surgical resection of VSs more difficult (associated with higher facial neuropathies and STR rates) after initial treatment with SRS? RECOMMENDATION Level 3: If microsurgical resection is necessary after SRS, it is recommended that patients be counseled that there is an increased likelihood of a STR and decreased FN function. The full guideline can be found at: https://www.cns.org/guidelines/guidelines-management-patients-vestibular-schwannoma/chapter_8.
Diagnosis and Outcome of Biopsies of Indeterminate Lesions of the Cavernous Sinus and Meckel's Cave: A Retrospective Case Series in 85 Patients
Hughes, Joshua , Kapurch, Joseph, Meyer, Fredric B. , Pollock, Bruce E. , Link, Michael J. , Hughes, Joshua D, Gompel, Jamie J. Van , Atkinson, John P.

Mayo Clinic

Neurosurgery | October 27, 2017 | Volume: 83 | Issue: 3 | Pages: 529-539

10.1093/neuros/nyx501 | PMID 29040711 Get It

Abstract BACKGROUND When clinical presentation, laboratory studies, or imaging cannot diagnose cavernous sinus (CS) and/or Meckel's cave (MC) lesions, biopsy may be necessary. OBJECTIVE To review our institutional series of biopsies of indeterminate CS and MC lesions. METHODS Records from January 1994 to June 2016 were searched for biopsied indeterminate CS and MC lesions. We defined indeterminate as having an atypical imaging appearance or a broad differential and the need for tissue for definitive diagnosis. We defined primary tumors as originating from cells inherent or near the CS and MC. RESULTS Eighty-five patients were included (median age 59 [2-85] yr); 22 (28%) had a cancer history. Approaches included frontotemporal craniotomy (n = 48, 56%), endoscopic endonasal (n = 20, 24%), percutaneous transforamen ovale (n = 12, 14%), or retrosigmoid craniotomy (n = 5, 6%). Final diagnosis was metastatic in 27 (32%), primary in 21 (25%), inflammatory in 13 (15%), hematologic in 11 (13%), fungal in 5 (5%), and nondefinitive or nondiagnostic in 8 (10%) patients. Thirteen (59%) patients with a cancer history (n = 22) had a diagnosis consistent with their prior cancer; the remaining had a second pathology (n = 6, 27%) or nondiagnostic biopsy (n = 3, 14%). Two patients had surgical complications resulting in death. CONCLUSION In this patient cohort, metastatic tumors were the most likely pathology. The biopsy threshold should be lower in patients with a cancer history if clinical or radiographic diagnosis is uncertain as 27% had a second disease. However, we consider biopsy as a last resort because the risk of major morbidity/mortality, while low, is not zero.
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry
Lewczuk, Piotr , Riederer, Peter , Verbeek, Marcel M. , Dubois, Bruno , Visser, Pieter Jelle , Engelborghs, Sebastiaan , Ramı́rez, Alfredo , Parnetti, Lucilla , Jack, Clifford R. , Teunissen, Charlotte E. , Hampel, Harald , Lleó, Alberto , Jessen, Frank , Glodzik, Lidia , Leon, Mony J. de , Fagan, Anne M. , Molinuevo, José Luís , Jansen, Willemijn J. , Winblad, Bengt , Shaw, Leslie M. , Andréasson, Ulf , Otto, Markus , Mollenhauer, Brit , Wiltfang, Jens , Turner, Martin R. , Zerr, Inga , Handels, Ron , Thompson, Alexander G. , Johansson, Gunilla , Ermann, Natalia, Trojanowski, John Q. , Karaca, Ilker, Wagner, Holger, Oeckl, Patrick , Doorn, Linda van Waalwijk van, Bjerke, Maria , Kapogiannis, Dimitrios , Kuiperij, H. Bea , Farotti, Lucia , Li, Yi , Gordon, Brian A. , Vos, Stephanie J. B. , Klijn, Catharina J.M. , Nostrand, William E. Van , Schmitz, Matthias , Gallo, Carla , Mato, Andrea Lopez, Thibaut, Florence , Lista, Simone , Alcolea, Daniel , Blennow, Kaj , Kornhuber, Johannes , Thibaut, on Behalf of the Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence, Verbeek, Marcel M , Ramirez, Alfredo , Parnetti, Lucilla , Jack, Clifford R , Lleó, Alberto , Handels, Ron , Thompson, Alexander G , Trojanowski, John Q , Gordon, Brian A , Thibaut, Florence , Alcolea, Daniel , Kornhuber, Johannes , Teunissen, Charlotte E , Turner, Martin R , Molinuevo, José Luis , O’Bryant, Sid E. , Jellinger, Kurt , Doorn, Linda Josephine Christine van Waalwijk van, Epelbaum, Stéphane , Minguillón, Carolina , Zetterberg, Henrik , Thibaut, on Behalf of the Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence, Wiltfang, Jens , Otto, Markus

Mayo Clinic

The World Journal of Biological Psychiatry | October 27, 2017 | Volume: 19 | Issue: 4 | Pages: 244-328

10.1080/15622975.2017.1375556 | PMID 29076399 Get It

Concise Review: Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine
Samsonraj, Rebekah M. , Raghunath, Michael , Nurcombe, Victor , Hui, James Hoi Po , Wijnen, André J. van , Cool, Simon M. , van Wijnen, Andre J

Mayo Clinic

Stem Cells Translational Medicine | October 27, 2017 | Volume: 6 | Issue: 12 | Pages: 2173-2185

10.1002/sctm.17-0129 | PMID 29076267 Get It

Abstract Mesenchymal stem cells (MSC) hold great potential for regenerative medicine because of their ability for self-renewal and differentiation into tissue-specific cells such as osteoblasts, chondrocytes, and adipocytes. MSCs orchestrate tissue development, maintenance and repair, and are useful for musculoskeletal regenerative therapies to treat age-related orthopedic degenerative diseases and other clinical conditions. Importantly, MSCs produce secretory factors that play critical roles in tissue repair that support both engraftment and trophic functions (autocrine and paracrine). The development of uniform protocols for both preparation and characterization of MSCs, including standardized functional assays for evaluation of their biological potential, are critical factors contributing to their clinical utility. Quality control and release criteria for MSCs should include cell surface markers, differentiation potential, and other essential cell parameters. For example, cell surface marker profiles (surfactome), bone-forming capacities in ectopic and orthotopic models, as well as cell size and granularity, telomere length, senescence status, trophic factor secretion (secretome), and immunomodulation, should be thoroughly assessed to predict MSC utility for regenerative medicine. We propose that these and other functionalities of MSCs should be characterized prior to use in clinical applications as part of comprehensive and uniform guidelines and release criteria for their clinical-grade production to achieve predictably favorable treatment outcomes for stem cell therapy.
The Southampton Consensus Guidelines for Laparoscopic Liver Surgery
Hilal, Mohammad Abu , Aldrighetti, Luca , Dagher, Ibrahim, Troisi, Roberto , Alikhanov, Ruslan , Aroori, Somaiah , Belli, Giulio, Besselink, Marc G. , Briceño, Javier , Gayet, Brice, D’Hondt, Mathieu , Lesurtel, Mickaël , Menon, Krishna , Lodge, Peter, Rotellar, Fernando , Santoyo, Julio Santoyo , Scatton, Olivier , Sutcliffe, Robert P. , Dam, Ronald M. van , White, Steve, Halls, Mark , Cipriani, Federica , Poel, M. van der, Ciria, Rubén , Barkhatov, Leonid , Gomez-Luque, Yrene, Ocana-Garcia, Sira, Cook, Andrew , Buell, Joseph F. , Clavien, Pierre‐Alain , Dervenis, Christos, Fusai, Giuseppe , Lang, Hauke , Primrose, John , Taylor, Mark , Gulik, Thomas van , Wakabayashi, Go , Asbun, Horacio J. , Cherqui, Daniel , Asbun, Horacio, Ciria, Ruben , Aldrighetti, Luca , Edwin, Bjørn , Besselink, Marc G , Soubrane, Olivier , Poel, Marcel J. van der , Geller, David A. , Rotellar, Fernando , Lesurtel, Mickaël , Cipriani, Federica

Mayo Clinic

Annals of Surgery | October 24, 2017 | Volume: 268 | Issue: 1 | Pages: 11-18

10.1097/sla.0000000000002524 | PMID 29064908 Get It

Objective: The European Guidelines Meeting on Laparoscopic Liver Surgery was held in Southampton on February 10 and 11, 2017 with the aim of presenting and validating clinical practice guidelines for laparoscopic liver surgery. Background: The exponential growth of laparoscopic liver surgery in recent years mandates the development of clinical practice guidelines to direct the speciality's continued safe progression and dissemination. Methods: A unique approach to the development of clinical guidelines was adopted. Three well-validated methods were integrated: the Scottish Intercollegiate Guidelines Network methodology for the assessment of evidence and development of guideline statements; the Delphi method of establishing expert consensus, and the AGREE II-GRS Instrument for the assessment of the methodological quality and external validation of the final statements. Results: Along with the committee chairman, 22 European experts; 7 junior experts and an independent validation committee of 11 international surgeons produced 67 guideline statements for the safe progression and dissemination of laparoscopic liver surgery. Each of the statements reached at least a 95% consensus among the experts and were endorsed by the independent validation committee. Conclusion: The European Guidelines Meeting for Laparoscopic Liver Surgery has produced a set of clinical practice guidelines that have been independently validated for the safe development and progression of laparoscopic liver surgery. The Southampton Guidelines have amalgamated the available evidence and a wealth of experts’ knowledge taking in consideration the relevant stakeholders’ opinions and complying with the international methodology standards.
Alveolar air and oxidative metabolic demand during exercise in healthy adults: the role of single-nucleotide polymorphisms of the β 2 AR gene
Iterson, Erik H. Van , Snyder, Eric M., Johnson, Bruce D., Van Iterson, Erik H

Mayo Clinic

Physiological Reports | October 23, 2017 | Volume: 5 | Issue: 20 | Pages: e13476

10.14814/phy2.13476 | PMID 29061864 Get It

Chronic subthreshold cortical stimulation for adult drug-resistant focal epilepsy: safety, feasibility, and technique
Kerezoudis, Panagiotis , Stead, Matthew, Shin, Cheolsu, Cascino, Gregory D. , Brinkmann, Benjamin H. , Lundstrom, Brian Nils, Brinkmann, Benjamin H , Grewal, Sanjeet S. , Lundstrom, Brian N. , Britton, Jeffrey W. , Worrell, Gregory A. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurosurgery | October 20, 2017 | Volume: 129 | Issue: 2 | Pages: 533-543

10.3171/2017.5.jns163134 | PMID 29053073 Get It

OBJECTIVEEpilepsy surgery is effective for lesional epilepsy, but it can be associated with significant morbidity when seizures originate from eloquent cortex that is resected. Here, the objective was to describe chronic subthreshold cortical stimulation and evaluate its early surgical safety profile in adult patients with epilepsy originating from seizure foci in cortex that is not amenable to resection.METHODSAdult patients with focal drug-resistant epilepsy underwent intracranial electroencephalography monitoring for evaluation of resection. Those with seizure foci in eloquent cortex were not candidates for resection and were offered a short therapeutic trial of continuous subthreshold cortical stimulation via intracranial monitoring electrodes. After a successful trial, electrodes were explanted and permanent stimulation hardware was implanted.RESULTSTen patients (6 males) who underwent chronic subthreshold cortical stimulation between 2014 and 2016 were included. Based on radiographic imaging, intracranial pathologies included cortical dysplasia (n = 3), encephalomalacia (n = 3), cortical tubers (n = 1), Rasmussen encephalitis (n = 1), and linear migrational anomaly (n = 1). The duration of intracranial monitoring ranged from 3 to 20 days. All patients experienced an uneventful postoperative course and were discharged home with a median length of stay of 10 days. No postoperative surgical complications developed (median follow-up length 7.7 months). Seizure severity and seizure frequency improved in all patients.CONCLUSIONSThe authors’ institutional experience with this small group shows that chronic subthreshold cortical stimulation can be safely and effectively performed in appropriately selected patients without postoperative complications. Future investigation will provide further insight to recently published results regarding mechanism and efficacy of this novel and promising intervention.